ProMetic Life Sciences Inc. (PLI) 2001年年度报告「TSX」.pdf

1、a company with its eyeon the present and the future6100 Royalmount AvenueMontreal,QuebecCanada H4P 2R2Tel.:(514)496-2115Fax:(514)496-annual report 2001Table of contentsProMetic annual report 2001345710141821244647484950HighlightsMessage to ShareholdersGrowth Engine=Core Technology+Core CompetencyInf

2、lammationCancerInfectious diseasesManagement Discussion andAnalysis of the Financial Positionand Operating ResultsFinancials24.Managements Report&Auditors Report to the Shareholders25.Consolidated Balance Sheets26.Consolidated Statements of Operations and Deficit27.Consolidated Statements of Cash Fl

3、owsBoard of DirectorsScientific Advisory CommitteeClinical Advisory Committee(Arriva-ProMetic,Inc.)Additional investor informationContact informationProMetic Business ModelThe Company fosters growth by offering itsenabling technology under license to pharma-ceutical and biotech companies so as to al

4、lowthem to develop proprietary products that rely onProMetics technology.ProMetic expects to generate long-term annuityrevenues from its license and long-term supplyagreements that enter into effect once its clientsproducts attain commercial status.ProMetic further leverages its core technologiesby

5、developing in-house high-value therapeuticsand medical applications,and limits its risk exposure through partnerships with multinationalsfor product development,clinical trials and marketing.CancerMimetic LigandInflammation81116HighlightsProMetic annual report 20014 Strategic Alliance with Merck KGa

6、A Purification of Monoclonal Antibodies Execution of a Memorandum of Understanding for the Formation ofa Joint Venture Company with the American Red Cross Detection and Removal of Viruses and Prions Completion of the Strategic Agreement with PharmAAware Sepsis B.V.for theDiagnosis and Treatment of S